10 March 2023

We’re happy to announce our upcoming webinar series on Gene Therapy co-organized by EURO-NMD, ERN-RND, for rare neurological diseases, ERN EpiCARE, for rare and complex epilepsies  and European Academy of Neurology (EAN), where we’ll delve into the latest advancements and breakthroughs in this interesting field. Click here to register!   …TIMESLOT: 18 April 2024 16:00 – 17:00 CEST   …THEME: “Lessons learned across different disorders and challenges in the development of gene therapies & The regulatory approach to evaluating and approving GT for neurological and other rare disorders” (hosted by ERN EURO-NMD)   …PRESENTER(S):

Dr. Kathrin Meyer (Nationwide Children’s Hospital, Columbus, Ohio, USA)

Dr. Meyer studied molecular and cellular biology at the University of Berne, Switzerland followed by a post-doctoral fellowship at Nationwide Children’s Hospital, Columbus Ohio, USA developing different therapeutic approaches for the neuromuscular disease Spinal Muscular Atrophy including the now approved AAV gene therapy Zolgensma. In 2017, she established her independent laboratory at the Center for Gene Therapy at Nationwide Children’s Hospital and became Assistant Professor at The Ohio State University, Columbus, Ohio. Her research focused on the development of novel in vitro models to study disease mechanisms and generation of novel therapeutics for neurological disorders with emphasis on neurodevelopmental and autism spectrum disorders. She also optimized cerebrospinal fluid delivery methods for delivery of therapeutics including AAVs to the nervous system and translated several additional AAV gene therapies to clinic. She served and continues to serve on scientific advisory boards for patient foundations and is Chief Scientific Advisor to Alcyone Therapeutics.  

Marta Kollb-Sielecka (European Medicines Agency, The Netherlands)

Marta Kollb-Sielecka joined the European Medicines Agency in 2013. She is a Product Lead in the Therapies for neurological and psychiatric disorders office as well as a member of Advanced Therapies Medicinal Products matrix team.  She holds a Master’s degree in Pharmacy from Warsaw Medical University. Prior to joining the Agency, she held a number of positions in pharmaceutical industry.      

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern